BNP Blood Test: Normal Range, Results, and What They Mean

Key Takeaways

• What it measures: Ventricular wall stress; BNP levels rise when the heart is working harder than normal due to elevated filling pressures, volume overload, or increased afterload.
• Typical reference range: BNP below 35 pg/mL (non-acute rule-out per 2021 ESC Guidelines); below 100 pg/mL (acute rule-out). NT-proBNP below 125 pg/mL (non-acute); age-stratified rule-in thresholds of 450/900/1,800 pg/mL for under 50/50-75/over 75 years.
• Sample type: EDTA plasma for BNP; serum or plasma for NT-proBNP. BNP and NT-proBNP are different assays with different reference ranges — not interchangeable.
• Fasting required: No.
• When providers order it: Acute shortness of breath, suspected heart failure, dyspnea workup, serial monitoring in known heart failure.
• Test frequency: Ordered as needed; repeated during active heart failure management to monitor response to therapy.
• Key confounder: Obesity lowers BNP; kidney disease elevates NT-proBNP disproportionately; sacubitril/valsartan raises BNP while lowering NT-proBNP.

What BNP Is and What It Measures

BNP (B-type natriuretic peptide, also called brain natriuretic peptide) is a 32-amino-acid cardiac hormone released by the ventricles of the heart in response to increased wall stress or volume overload. When the heart is working harder than normal — from heart failure, valve disease, elevated blood pressure, pulmonary embolism, or other causes — ventricular cardiomyocytes synthesize and release BNP as a compensatory signal that promotes vasodilation and fluid excretion. BNP measurement in blood serves as a biomarker of cardiac stress used by clinicians for diagnostic and prognostic purposes: its concentration reflects the degree of hemodynamic burden on the heart at the time of sampling.

BNP and its co-secreted fragment, NT-proBNP, are both produced from the same precursor (proBNP) but differ in half-life, clearance mechanism, and clinical reference intervals. BNP has a half-life of approximately 20 minutes, cleared by neprilysin and NPR-C receptors; NT-proBNP has a half-life of 1 to 2 hours, cleared primarily through renal filtration. This difference in clearance explains why NT-proBNP is more markedly elevated in chronic kidney disease and why the two tests produce numerically different results from the same blood draw. Daniels and Maisel, in their 2007 state-of-the-art review in the Journal of the American College of Cardiology, reviewed the diagnostic and prognostic use of natriuretic peptides, establishing the framework for clinical use that current guidelines build on.

BNP and NT-proBNP Reference Ranges

Reference values depend on clinical context (acute presentation vs. non-acute monitoring), patient characteristics, and assay platform. The values below are from current clinical guidelines and landmark validation studies.

• BNP — Non-acute heart failure rule-out: Below 35 pg/mL (2021 ESC Guidelines)
• BNP — Acute dyspnea rule-out: Below 100 pg/mL
• BNP — Acute dyspnea rule-in (higher probability of HF): Above 400 pg/mL
• BNP — Gray zone (indeterminate): 100 to 400 pg/mL
• NT-proBNP — Non-acute heart failure rule-out: Below 125 pg/mL
• NT-proBNP — Acute dyspnea rule-out: Below 300 pg/mL
• NT-proBNP — Acute HF rule-in, age under 50: Above 450 pg/mL
• NT-proBNP — Acute HF rule-in, age 50 to 75: Above 900 pg/mL
• NT-proBNP — Acute HF rule-in, age over 75: Above 1,800 pg/mL

Reference ranges vary by laboratory and individual. The values above represent guideline-derived clinical reference intervals from McDonagh and colleagues, published in the European Heart Journal in 2021, and from Januzzi and colleagues in the ICON and ICON-RELOADED studies. These are not absolute diagnostic thresholds — your provider will interpret your specific result alongside symptoms, medical history, and other test findings.

The age-stratified NT-proBNP thresholds deserve emphasis. Januzzi and colleagues, in the original ICON pooled analysis published in the European Heart Journal in 2006, established age-stratified NT-proBNP cut-points — findings that were validated in the contemporary ICON-RELOADED study reported by Januzzi and colleagues in the Journal of the American College of Cardiology in 2018, refining thresholds in a modern ED population. A single universal NT-proBNP cutoff applied across age groups would misclassify a large proportion of older patients with genuine cardiac pathology.

What Causes Elevated BNP Levels

Elevated BNP does not always indicate the most serious cause. Context and clinical picture determine significance.

Cardiac causes

Heart failure is the most common and most strongly associated cause of significantly elevated BNP. Both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) produce elevated BNP, though the magnitude of elevation varies. Ammar and colleagues, in a 2025 systematic review and meta-analysis published in Heart Failure Reviews, showed that BNP and NT-proBNP predict HFpEF outcomes, confirming the marker's prognostic utility across heart failure subtypes. Latini and colleagues, in the Val-HeFT analysis published in the European Heart Journal in 2004, showed BNP outperforms other neurohormones in HF, establishing the prognostic dimension of elevated levels. Other cardiac causes include:

• Heart failure with reduced ejection fraction (HFrEF) — often the highest elevations; BNP frequently above 400 pg/mL
• Heart failure with preserved ejection fraction (HFpEF) — elevated but often more moderate than HFrEF
• Valvular heart disease — aortic stenosis and mitral regurgitation cause ventricular pressure or volume overload
• Left ventricular hypertrophy — increased wall mass raises baseline wall stress
• Acute myocardial infarction — ischemia-driven elevation; Souza and colleagues, in a 2020 paper in Arquivos Brasileiros de Cardiologia, showed NT-proBNP prognosis in acute coronary syndrome
• Atrial fibrillation — atrial stretch drives secretion independent of ventricular function

Non-cardiac causes

Elevated BNP is not specific to cardiac disease. Maeder and Rickli, in a 2008 review in the International Journal of Cardiology, reviewed cardiac and non-cardiac BNP elevation in a practical clinical-care framework.

• Pulmonary embolism — right ventricular strain elevates BNP through right-sided wall stress; Kucher, in a 2006 review in Seminars in Thrombosis and Hemostasis, showed BNP and RV dysfunction in acute PE
• Chronic kidney disease — impaired NT-proBNP clearance raises values independent of cardiac pathology
• Sepsis and critical illness — cytokine-mediated cardiac stress can elevate BNP; Khoury and colleagues, in a 2017 Journal of Critical Care paper, demonstrated BNP prognosis in non-cardiac sepsis
• Severe anemia — compensatory cardiac output increase raises wall stress
• Hyperthyroidism — elevated cardiac output

Physiologic and pharmacological causes

Age and sex independently elevate BNP and NT-proBNP without implying cardiac pathology. Wang and colleagues, in the 2002 American Journal of Cardiology study, documented age and sex effects on NP levels. Redfield and colleagues, in the Olmsted County community study published in 2002, showed plasma BNP rises with age and sex in a general community population not selected for cardiac disease.

What Causes Lower-Than-Expected BNP Levels

Low BNP in a clinically appropriate patient does not always rule out cardiac pathology. The most important clinical scenario is obesity.

Obesity-related attenuation

Adipose tissue expresses high concentrations of NPR-C clearance receptors, which bind and internalize natriuretic peptides. The net effect is lower circulating BNP and NT-proBNP in individuals with elevated BMI. Wang and colleagues, in the 2004 Circulation study, documented the inverse BMI and natriuretic peptide relationship in a large clinical population. Khan and colleagues, in a 2011 community-based confirmation, confirmed that obesity lowers natriuretic peptide concentrations. The clinical implication is significant: a BNP within the "normal" range in a symptomatic patient with obesity should not be interpreted as evidence against cardiac pathology without considering this confounding effect.

Sacubitril/valsartan treatment

The heart failure medication sacubitril/valsartan (Entresto) inhibits neprilysin, the enzyme responsible for BNP degradation. This paradoxically raises circulating BNP levels even as cardiac function improves, making BNP an unreliable monitoring biomarker in patients on this therapy. McMurray and colleagues, in the pivotal PARADIGM-HF trial published in the New England Journal of Medicine in 2014, established sacubitril/valsartan for heart failure, providing the clinical context for why many current heart failure patients are on this combination. Myhre and colleagues, in a 2019 PARADIGM-HF biomarker analysis published in the Journal of the American College of Cardiology, showed BNP rises and NT-proBNP falls on Entresto. NT-proBNP is the clinically appropriate monitoring marker for patients on Entresto.

Factors That Affect BNP Results

The following factors independently influence BNP or NT-proBNP values and should be considered when interpreting any result.

• Age — Raises levels: Values increase progressively with age. Age-stratified thresholds are the clinical standard for NT-proBNP. Welsh and colleagues, in a large general-population cohort published in Circulation: Heart Failure in 2022, derived NT-proBNP reference ranges and age.
• Female sex — Raises levels: Women have higher values than men across all age groups. Mechanism involves estrogen effects on natriuretic peptide clearance.
• Obesity (BMI above 30) — Lowers levels: Adipose NPR-C receptor expression clears natriuretic peptides; results in obese patients may underestimate cardiac risk.
• Renal impairment — Raises NT-proBNP more than BNP: Neuen and colleagues, in a 2025 paper in JACC Heart Failure, demonstrated how kidney function modulates NP concentrations and outcomes in HFpEF. Interpret with eGFR context.
• Sacubitril/valsartan — Raises BNP, lowers NT-proBNP: Neprilysin inhibition blocks BNP degradation; use NT-proBNP for monitoring in treated patients.
• Atrial fibrillation — Raises levels: Atrial stretch from AF elevates natriuretic peptide secretion independent of ventricular function.
• Acute pulmonary embolism — Raises levels: Right ventricular strain elevates BNP through right-sided wall stress mechanisms.
• Critical illness and sepsis — May raise levels: Khoury and colleagues documented prognostic BNP elevation in non-cardiac sepsis. Non-cardiac elevation does not carry the same diagnostic implications as cardiac-origin elevation.

How BNP Testing Works

What type of sample is used

BNP is measured from EDTA plasma, collected in a purple-top (K2EDTA) tube. NT-proBNP is measured from serum or plasma depending on the laboratory's assay platform. Because the two tests use different analytical configurations, results are not numerically equivalent — a BNP of 150 pg/mL and an NT-proBNP of 150 pg/mL are entirely different clinical findings. Yeo and colleagues, in a 2005 Journal of Cardiac Failure study, documented the differences between BNP and NT-proBNP assays in direct comparison, providing the foundation for understanding why labs report different reference intervals for each. Masson and colleagues, in the Val-HeFT head-to-head analysis, confirmed differences in dynamic range and kinetics between the two markers in chronic heart failure.

Fasting requirements

No fasting is required for BNP or NT-proBNP testing. Meal intake does not acutely alter cardiac wall stress sufficiently to affect results clinically. Vigorous exercise immediately before collection may transiently affect values; standard collection conditions apply.

Timing and specimen stability

BNP is relatively unstable at room temperature and should be processed within two to four hours of collection to prevent degradation-related underestimation. NT-proBNP is more stable and tolerates longer transport at refrigerated temperatures. Results are typically available within hours in most clinical laboratory settings. Neither marker shows significant circadian variation under stable clinical conditions.

Interpreting the gray zone (100 to 400 pg/mL for BNP)

Results in the intermediate range between rule-out and rule-in thresholds are the most clinically complex. Brenden and colleagues, in a REDHOT sub-analysis published in the American Heart Journal in 2006, specifically analyzed gray-zone BNP levels between 100 and 400 pg/mL, confirming that these values do not reliably predict the presence or absence of heart failure and require interpretation alongside clinical findings and additional testing. Daniels and colleagues, in the REDHOT study, found clinician severity vs BNP levels, reinforcing the value of objective measurement but also its limits in the gray zone.

Which Biomarkers Are Worth Testing Alongside BNP

BNP and NT-proBNP rarely tell the complete story in isolation. The most informative cardiac evaluations combine these markers with complementary measures.

• Troponin (I or T): Marker of myocardial cell injury. Troponin testing alongside BNP helps distinguish cardiac wall stress from active myocardial damage. In acute presentations, both may be elevated simultaneously, each providing different clinical information.
• hs-CRP: Systemic inflammatory marker. Inflammation is a driver of cardiac remodeling and contributes to heart failure progression. An elevated hs-CRP alongside elevated BNP provides context about inflammatory burden alongside hemodynamic stress.
• Creatinine and eGFR: Renal function profoundly affects NT-proBNP clearance and baseline values. Creatinine measurement is essential for accurate NT-proBNP interpretation, particularly in older patients and those with known kidney disease.
• Lipid panel: Atherosclerotic disease is the leading driver of ventricular dysfunction. A comprehensive lipid panel alongside BNP provides context for the cardiovascular risk driving cardiac stress. The cardiovascular health biomarker guide covers these markers in combination.

When to Take This Seriously

A single elevated BNP result is not a diagnosis of heart failure. Elevated values appear in older adults, individuals with obesity, those with kidney disease, and patients with atrial fibrillation for reasons unrelated to primary ventricular dysfunction. What warrants prompt provider evaluation is an elevated BNP in the context of symptoms — shortness of breath, leg swelling, fatigue with exertion, or reduced exercise tolerance. An isolated mildly elevated BNP in an asymptomatic 75-year-old differs substantially in clinical meaning from the same value in a 45-year-old with acute dyspnea. A BNP result substantially above the rule-in threshold, particularly when accompanied by symptoms, generally prompts echocardiographic evaluation and clinical follow-up.

Bayes-Genis and colleagues, in the 2023 HFA-ESC clinical consensus published in the European Journal of Heart Failure, provided NT-proBNP algorithms for early HF diagnosis that map specific NT-proBNP bands to clinical actions — the most current evidence-based framework for converting a result into a clinical decision. The 2021 ESC Guidelines, published by McDonagh and colleagues, define when BNP warrants echocardiography.

Understanding your cardiovascular baseline, including complementary markers like hs-CRP for inflammation, gives your provider the reference context that makes any future cardiac result more interpretable. For a broader view of cardiovascular and cardiac biomarker testing together, see the BNP test.

IMPORTANT SAFETY INFORMATION

BNP (B-type natriuretic peptide) and NT-proBNP are diagnostic biomarkers used by healthcare providers to evaluate cardiac stress and heart failure. This article is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment guidance.

Reference ranges for BNP and NT-proBNP vary by assay platform, age, sex, clinical context, and renal function. The threshold values cited in this article reflect guideline-derived population reference intervals; they are not universal diagnostic cutoffs. A result above or below any threshold cited here does not establish a diagnosis and should not be acted upon independently of provider evaluation.

Multiple conditions and medications affect natriuretic peptide levels. Obesity lowers values; kidney disease and advancing age raise values; sacubitril/valsartan raises BNP while lowering NT-proBNP. Result interpretation requires knowledge of these confounders. Consult a qualified healthcare provider for evaluation and interpretation of any laboratory result.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. BNP and NT-proBNP results must be interpreted by a qualified healthcare provider alongside symptoms, medical history, and other clinical findings. Reference ranges vary by assay, age, sex, and patient characteristics.